Effectiveness of the Oxford-AstraZeneca COVID-19 vaccine as a 2nd booster, the REFORCO-Brazil study

Trial Identifier:	D8111R00028
Sponsor:	AstraZeneca
NCTID::	NCT05697705
Start Date:	July 2022
Primary Completion Date:	April 2023
Study Completion Date:	April 2023
Condition:	COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Brazil	São Paulo, Brazil, 05403-010

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.